Tissue Chip for Drug Screening
To help streamline the therapeutic development pipeline, NIH, in collaboration with the Defense Advanced Research Projects Agency (DARPA) and the U.S. Food and Drug Administration, is leading an initiative to improve the process for predicting whether drugs will be safe in humans.
The Tissue Chip for Drug Screening initiative, which marks the first interagency collaboration launched by NCATS, aims to develop 3-D human tissue chips that accurately model the structure and function of human organs, such as the lung, liver and heart. Once developed, researchers can use these models to predict whether a candidate drug, vaccine or biologic agent is safe or toxic in humans in a faster and more cost-effective way than current methods.
More than 30 percent of promising medications have failed in human clinical trials because they are determined to be toxic despite promising pre-clinical studies in animal models. Tissue chips are a newer human, cell-based approach. These models may enable scientists to predict more accurately how effective a therapeutic candidate would be in clinical studies.
Eliminating toxic and/or ineffective drugs earlier in the development process would save time and money. These human tissue chips also could teach us a great deal about disease progression, enabling researchers to better prevent, diagnose and treat such conditions.
A Unique Partnership
To design and develop the tissue chips, NCATS, DARPA and the FDA are focusing resources and brain power in a novel collaboration.
In 2011, NIH’s Common Fund and National Institute of Neurological Disorders and Stroke led trans-NIH efforts aimed at better understanding how tissue chips work. Seeking the best ideas in engineering, biology and toxicology, NIH issued two requests for applications in the fall of 2011: RFA-RM-11-022 and RFA-RM-12-001.
On July 24, 2012, NIH announced the resulting 17 awards to researchers who will work to develop human tissue chips that could better predict drug safety and efficacy before they are tested in people. Two additional awards funded by other NIH Institutes and Centers were issued in September. View the 2012 tissue chip awardees and learn more about funding for this program.
DARPA is conducting a separate but parallel program in close coordination with the NIH. It has entered into cooperative agreements with two NIH tissue chip award recipients (the Wyss Institute at Harvard University and MIT) to develop engineering platforms capable of integrating 10 or more organ systems.
FDA will help explore how this new technology might be used to assess drug safety prior to approval for first-in-human studies.
For More Information
NIH’s vision for NCATS was published July 6, 2011, in Science Translational Medicine.
- Reengineering Translational Science: The Time Is Right (PDF) by Francis S. Collins, M.D., Ph.D., NIH Director